Objective: The paper attempts to understand the medical security and disease burden of phenylketonuria (PKU) in Foshan City, and to explore the specific path to establish a multi-level medical security system of PKU in Foshan City. Methods: Based on policy literature research, questionnaire investigation, interviews, data collection and comparative analysis, we summarize relevant experience at home and abroad to comprehensively understand the guarantee level of PKU in Foshan City, and to simulate and predict the affordability of medical insurance fund after improving the guarantee level of patients with PKU. Results: The disease burden of patients with PKU is still heavy in Foshan City, and the accessibility of Food for Special Medical Purpose (FSMP) is still low. Improving the guarantee level of FSMP has a significant impact on the Special Fund for Neonatal Screening of Foshan Women and Children Hospital, which is the main source of security, and the sustainability of security is insufficient. The supplementary medical insurance fund will be able to support the inclusion of FSMP into the scope of inclusive commercial supplementary medical insurance. The basic medical insurance fund can be affordable to include PKU into the scope of Outpatient Special Diseases. Conclusion: A multi-level security system for PKU can be established by including FSMP into the coverage of inclusive commercial supplementary medical insurance, including PKU into the management of Outpatient Special Diseases guaranteed by basic medical insurance, appropriately extending the conditions for the identification of medical assistance for PKU, strengthening multi-sector cooperation, giving full play to the role of charitable donations and social assistance and security, establishing a multi-level security system for PKU and improving the security level of PKU patients in Foshan.
Key words
phenylketonuria /
multi-level medical security /
food for special medical purpose
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 国家卫生健康委办公厅.关于印发罕见病诊疗指南(2019年版)通知[EB/OL].(2019-02-28)[2023-04-18].http://www.gov.cn/fuwu/2019-02/28/content_5369203.html.
[2] 刘雯,杨玲,白雪峰,等.中国罕见病研究和诊治——突飞猛进的10年[J].中国优生与遗传杂志,2022,30(10):1695-1698.
[3] 高平明,戴怡蘅,黄建伟,等.佛山市350821名新生儿苯丙酮尿症筛查回顾性分析[J].中国妇幼保健,2007,(14):1949-1950.
[4] 顾学范,王治国.中国580万新生儿苯丙酮尿症和先天性甲状腺功能减低症的筛查[J].中华预防医学杂志,2004,(02):99-102.
[5] 王泽钊,宋晓琳,张金子,等.国外罕见病治疗保障体系对我国的伦理启示[J].中国医学伦理学,2022,35(10):1088-1093.
[6] 祁晓峰,张昊昱,李晓霞,等.1981—2019年河北省新生儿苯丙酮尿症的筛查分析[J].中国优生与遗传杂志,2021,29(02):241-242.
[7] 穆文娟,郝丽婷,杨建平,等.山西省277例苯丙酮尿症患儿智力影响因素分析[J].中国妇幼健康研究,2023,34(03):63-68.
[8] 秦芊芊.广东省超罕见病患者生存现况与医疗保障模式研究[D].暨南大学,2021.
[9] 陈馨仪.重庆市罕见病患者现状及保障对策研究[D].重庆医科大学,2021.
[10] 鲁晨辉,何永熙,魏皓东,等.关于苯丙酮尿症特殊医学用途配方食品研发与应用进展[J].食品工业科技,2022,43(16):413-420.
[11] 孙琳琳.特殊医学用途婴儿配方粉辅助治疗苯丙酮尿症患儿的效果分析[J].中国实用乡村医生杂志,2022,29(05):18-20.
[12] 中华预防医学会出生缺陷预防与控制专业委员会新生儿筛查学组,中华医学会儿科学分会临床营养学组,中国医师协会医学遗传医师分会临床生化遗传专业委员会,等.苯丙氨酸羟化酶缺乏症饮食治疗与营养管理共识[J].中华儿科杂志,2019,57(06):405-409.
[13] 胡宏伟.科学确定重特大疾病医疗保险和救助对象范围,提升保障精准度[J].中国医疗险,2021,158(11):45-46.
[14] 国务院办公厅.关于健全重特大疾病医疗保险和救助制度的意见[EB/OL].(2021-11-19)[2023-04-18].http://www.gov.cn/zhengce/content/2021-11/19/content_5651446.html.
[15] 广东省人民政府办公厅.关于健全重特大疾病医疗保险和救助制度的实施意见[EB/OL].(2022-12-22)[2023-04-18].https://www.gd.gov.cn/xxts/content/post_4073274.html.
[16] 佛山市慈善会.爱满佛山,向善之城[J].大社会,2022(11).